We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02687724
Recruitment Status : Unknown
Verified July 2018 by University College Dublin.
Recruitment status was:  Recruiting
First Posted : February 22, 2016
Last Update Posted : July 19, 2018
Information provided by (Responsible Party):
University College Dublin

Brief Summary:
GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A nationwide multi-centred randomised controlled trial (RCT) investigating the use of GLM dose adjustment in ulcerative colitis (UC). The primary objective is to ascertain if dose adjustment of GLM based on GLM drug levels and FCP levels results in higher response and remission rates than standard SmPC dosing.

Condition or disease Intervention/treatment Phase
Colitis Drug: Golimumab (GLM) Phase 4

Detailed Description:

UC is a chronic inflammatory bowel disease (IBD) in which the lining of the large intestine become inflamed. There is no official database which gives accurate figures but it is thought that at least 20,000 people are living with IBD in Ireland. Males and females are affected equally and patients can be diagnosed at any age, including babies and children. The peak age of incidence is between the ages of 15 and 35, with a second (smaller) peak from the 50s to 70s.

GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology. It is part of the immunosuppressants pharmacotherapeutic group of TNF-α inhibitors. It is licensed for use in several chronic inflammatory conditions including UC, Psoriatic arthritis, axial spondylitis, rheumatoid arthritis.

The design of GOAL-ARC aims to address the impact of dose escalation of GLM immediately following induction and during the subsequent maintenance phase in response to suboptimal drugs levels or persisting inflammatory burden as represented by raised faecal calprotectin (FCP). FCP has been shown to correlate closely to endoscopic disease activity6.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 136 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC).
Study Start Date : June 2016
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : February 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Golimumab

Arm Intervention/treatment
Active Comparator: Standard treatment as per SmPC
Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 & 2. They will then receive 100mgs/ 50mgs depending on their weight as per SmPC. Patients will report their modified partial mayo score and SHS score every 4 weeks (PRO) and provide it to the investigator site via a web based application.
Drug: Golimumab (GLM)
GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology

Experimental: Intervention Arm
Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 & 2. As with Group 1, Patients will report their modified partial mayo and SHS score every four weeks ( the window for this will be +/- one week) and provide it to the investigator site via a web based application. In addition FCP, GLM DL and ADA shall be measured every four weeks.
Drug: Golimumab (GLM)
GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology

Primary Outcome Measures :
  1. Patient Continuous Clinical Response (pCCR) [ Time Frame: Wk 14 through to Wk 46 ]
    Absence of clinical flare, defined as an increase in modified partial Mayo score of 2 points value with accompanying requirement for treatment intervention

Secondary Outcome Measures :
  1. Total Mayo Score [ Time Frame: Week 1, Week 46 ]
    The Total Mayo Score is a combined endoscopic and clinical scale used to assess the severity of UC. It is a composite of sub-scores from four categories, including stool frequency, rectal bleeding, findings at endoscopy and physician global assessment (PGA), with a total score ranging from 0 - 12.

  2. Partial Mayo Score [ Time Frame: Week 14 ]
    Partial Mayo score consists of three subscores including stool frequency, rectal bleeding and PGA, a total score ranges from 0 - 9.

  3. Modified Partial Mayo Score [ Time Frame: Week 1 to Week 46 ]
    A modified partial Mayo score comprises of the two PRO sub-scores, rectal bleeding and stool frequency

  4. Week 14 Clinical Response [ Time Frame: Week 14 ]
    A decrease from BL in partial Mayo score by ≥30% or a decrease of 3 points. or A decrease from BL in modified partial Mayo of 2 points or a decrease of ≥30% from baseline.

  5. Clinical Remission [ Time Frame: Week 46 ]
    Clinical remission is defined as a Mayo score ≤2 points, with no individual sub-score >1.

  6. Clinical Flare [ Time Frame: Week 14 to Week 46 ]
    UC symptom recurrence as a defined by modified partial Mayo score increase of 2 points from week 14 value with accompanying requirement for treatment intervention

  7. Corticosteroid Free Remission [ Time Frame: Week 46 ]
    Clinical remission at WK 46 with no concomitant steroids

  8. Mucosal healing [ Time Frame: Week 46 ]
    A Mayo endoscopic subscore of 0 or 1

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients ≥ 18 years of age
  • Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol
  • Established diagnosis of UC and moderate-to-severe disease activity, defined as a Mayo score of 6-12, with an endoscopic subscore ≥2.
  • Patients had an inadequate response to, or had failed to tolerate, 1 or more of the following conventional therapies: oral 5-aminosalicylates, oral corticosteroids, azathioprine (AZA), and/or 6-mercaptopurine (6MP); or corticosteroid dependent (ie, an inability to taper corticosteroids without recurrence of UC symptoms).
  • Patients concurrently treated with oral 5-aminosalicylates or corticosteroids were to receive a stable dose for at least 2 weeks before baseline, and patients receiving AZA and/or 6MP were to receive a stable dose for at least 4 weeks before baseline. Patients were required to maintain stable doses of their concomitant UC medications during the study.
  • Female subjects of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 6 months thereafter OR
  • Surgical sterilized female patients with documentation of prior hysterectomy, tubal ligation or complete bilateral oophorectomy OR
  • Postmenopausal women with postmenopausal defined as permanent cessation >1 year of previously occurring menses.
  • Female subjects' serum pregnancy test performed at the screening visit and urine pregnancy test performed at the baseline visit must be negative.
  • Subjects have following investigations within 1 month prior to enrolment.
  • Routine bloods including U&E, FBC, LFTs, inflammatory markers (CRP) and albumin will be measured.
  • Medical history, concomitant medications
  • Intradermal reaction to Tuberculin (PPD skin test) or Mycobacterium tuberculosis antigenspecific interferon-gamma release assay (IGRA)
  • TB screening: chest X-Ray unless performed in the last 6 months
  • Stool examination for enteric pathogens including Clostridium difficile
  • Inclusion/exclusion criteria
  • Informed consent
  • Mayo score (including sigmoidoscopy unless performed in previous 3 months)
  • Patient's weight and height and abdominal circumference

Exclusion Criteria:

  • Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study
  • Patients aged <18 years of age
  • Patients who cannot give informed consent,
  • Pregnant patients or those who are breastfeeding will be deemed ineligible.
  • Prior treatment with any anti-TNF agent
  • Contra-indication to use of GLM (Hypersensitivity to the active substance or to any of the excipients; Active tuberculosis (TB), acute or chronic Hepatitis B infection or other severe infections such as sepsis and/or opportunistic infections including HIV infection; Moderate or severe heart failure (NYHA class III/IV)
  • Have symptoms or signs suggestive of current active or latent TB upon medical history, physical examination and/or chest radiograph, or positive Mycobacterium tuberculosis antigen-specific interferon-gamma release assay (IGRA)
  • Patients with a history of, or at imminent risk for, colectomy; who required gastrointestinal surgery within 2 months before screening;
  • History of colonic mucosal dysplasia or adenomatous colonic polyps that were not removed
  • Screening stool study positive for enteric pathogens or Clostridium difficile toxin.
  • Oral corticosteroids at a dose >40 mg prednisone or its equivalent per day; receipt of cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks before the first study agent injection; or use of an investigational agent within 5 half-lives of that agent before the first study agent injection.
  • Patients in recent receipt of live vaccinations within 4 weeks prior to enrolment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02687724

Layout table for location contacts
Contact: Peter Doran, PhD peter.doran@ucd.ie
Contact: Rabia Hussain rabia.hussain@ucd.ie

Layout table for location information
St Vincent's University Hospital Recruiting
Dublin, Ireland
Contact: Glen Doherty       g.doherty@st-vincents.ie   
Principal Investigator: Glen Doherty         
Sponsors and Collaborators
University College Dublin
Layout table for investigator information
Principal Investigator: Glen Doherty g.doherty@st-vincents.ie
Layout table for additonal information
Responsible Party: University College Dublin
ClinicalTrials.gov Identifier: NCT02687724    
Other Study ID Numbers: UCDCRC/15/007
First Posted: February 22, 2016    Key Record Dates
Last Update Posted: July 19, 2018
Last Verified: July 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Tumor Necrosis Factor Inhibitors
Anti-Inflammatory Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs